

**Managing common infections NICE guideline  
Committee meeting 20 NICE minutes**

**Date:** 13/11/18  
**Location:** NICE Office, Manchester  
**Minutes:** Final and confirmed

<b>Committee members present:</b>	
Tessa Lewis – Chair (TL)	Present for items 1 - 7
Kieran Hand (KH)	Present for items 1 - 7
Alastair Hay (AH)	Present for items 1 - 7
Ian Hill-Smith (IH)	Present for items 1 - 7
Susan Hopkins (SH)	Present for items 1 - 7
Clodna McNulty (CM)	Present for items part of 4 - 7
John Morris (JM)	Present for items 1 - 7
Mitul Patel (MP)	Present for items 1 - 7
Carole Pitkeathley (CP)	Present for items 1 - 7
Avril Tucker (AT)	Present for items 1 - 7
Tim Felton (TF) (Topic Expert)	Present for items 1 - 7

<b>In attendance (NICE):</b>	
Rachel Adams (RA)	Present for items 1 - 7
Sara Buckner (SB)	Present for items 1 - 7
Rupert Franklin (RF)	Present for items 1 - 7
Ruth Garnett (RG)	Present for items 1 - 7
James Jagaroo (JJ)	Present for items 1 - 4
Albany Meikle (AM)	Present for items 1 - 7
Louise Picton (LP)	Present for items 1 - 7
Ian Pye (IP)	Present for items 1 - 7

<b>Apologies</b>
Caroline Ward (CW)

<b>1. Welcome, introductions and apologies</b>
--

The chair welcomed the committee members and attendees to the 20<sup>th</sup> public health advisory committee D (PHAC D) meeting on managing common infections. The committee members and attendees introduced themselves.

The chair informed the committee that apologies had been received as noted above.

The chair outlined the objectives of the meeting, which included:

- discussion and agreement of skin and soft tissue infection review protocols
- discussion of evidence, draft recommendations for guidance on the treatment of pneumonia (hospital-acquired): antimicrobial prescribing
- discussion of evidence, draft recommendations for guidance on the treatment of pneumonia (community-acquired): antimicrobial prescribing

The minutes of the previous meeting were reviewed and agreed.

## 2. Declaration of interests

The chair asked the committee to declare any new or relevant interests

Name	Job title, organisation	Declarations of Interest
Mitul Patel	Consultant Microbiologist, Birmingham Children's Hospital	Poster accepted at Federation of Infection Societies 2018 Conference on Effect on Pre-admission antibiotics and its implication on outcome in cases of mastoiditis.
Mitul Patel	Consultant Microbiologist, Birmingham Children's Hospital	Chair, NICE Managing Common Infection Session on URTI and UTI at Federation of Infection Societies 2018 conference.
Susan Hopkins	Healthcare-Associated Infection & Antimicrobial Resistance, Deputy Director, National Infection Service, Public Health England	NICE Managing Common Infection Session at Federation of Infection Societies 2018 conference.
Kieran Hand	Consultant Pharmacist – Anti-infectives, University Hospital	Speaking at Federation of Infection Societies annual conference on the NICE guideline on Sore Throat

	Southampton NHS Foundation Trust	
Kieran Hand	Consultant Pharmacist – Anti-infectives, University Hospital Southampton NHS Foundation Trust	Advisory board honorarium from Merck Sharp & Dohme pharmaceuticals (manufacturers of antibiotics ceftolozane-tazobactam, daptomycin, ertapenem and tedezolid)
Kieran Hand	Consultant Pharmacist – Anti-infectives, University Hospital Southampton NHS Foundation Trust	Speaker honorarium from Merck Sharp & Dohme pharmaceuticals (manufacturers of antibiotics ceftolozane-tazobactam, daptomycin, ertapenem and tedezolid)
Tim Felton	Consultant in Intensive Care and Respiratory Medicine at Manchester University NHS Foundation Trust and Senior Lecture in the Division of Infection, Immunity and Respiratory Medicine at the University of Manchester	Attend advisory board for Menarini who have marketing authorisation for Meropenem–Vaborbactam. Meropenem–Vaborbactam is a novel antibiotic with activity covering resistant gram negative bacteria

The chair and a senior member of the NICE Development team (NDT) noted that KH would have to be fully excluded from the relevant sections of the meeting due to the declared interests. The interests declared by other members did not prevent the attendees from participating in the meeting at the chair's discretion.

### **3. Update on current topics and process**

RG updated the committee on the current topics and progress to date.

### **4. Discussion and agreement of skin and soft tissue infection review protocols**

JJ gave a presentation on the impetigo review protocol. The committee agreed the review protocol.

JJ gave a presentation on the infected eczema and psoriasis review protocol. The committee agreed the review protocol.

JJ gave a presentation on the insect bites and stings review protocol. The committee agreed the review protocol.

JJ gave a presentation on the animal bites review protocol. The committee agreed the review protocol. 10.55 CM joined the meeting

TL closed the meeting to the public.

11.10 JJ left the meeting.

#### **5. Discussion of evidence, draft recommendations for guidance on the treatment of pneumonia (hospital-acquired): antimicrobial prescribing**

AM presented the evidence for hospital acquired pneumonia. AM also made notes on an electronic version of the guideline during committee discussion.

11.35 KH left the meeting for the evidence presented on choice of antibiotics due to a previously declared interest.

11.40 AM left the meeting for the evidence presented on ceftriaxone due to a previously declared interest.

11.43 AM re-joined the meeting

AM summarised the evidence she had presented. The committee discussed the evidence presented.

11.50 KH re-joined the meeting

12.55 KH left the meeting for the discussion and agreement of specific antibiotics within the treatment table.

13.15 RF and RA left the meeting.

13:30 CP left the meeting

13.40 KH re-joined the meeting.

The committee discussed course length.

13.55 KH left the meeting

The committee discussed antibiotic choice.

13.55 RG and LP left the meeting.

## **6. Discussion of evidence, draft recommendations for guidance on the treatment of pneumonia (community-acquired): antimicrobial prescribing**

14:15 KH re-joined the meeting.

AM gave a presentation on the evidence for antibiotic treatment of community acquired pneumonia in adults. AM also made notes on an electronic version of the guideline during committee discussion. The committee discussed the evidence presented. The committee discussed course length.

14.40 RG and LP re-joined the meeting.

Following discussion the committee agreed a course length. The committee discussed and agreed the content of the antibiotic choice table.

AM gave a presentation on the evidence for antibiotic treatment of non-severe community acquired pneumonia in children. AM also made notes on an electronic version of the guideline during committee discussion. The committee discussed the evidence presented. The committee discussed and agreed the content of the antibiotic choice table.

AM presented the evidence for severe community acquired pneumonia in children.

15:45 AM left the meeting while LP presented the evidence for ceftriaxone due to a previously declared interest.

15:50 AM re-joined the meeting.

AM made notes on an electronic version of the guideline during committee discussion. The committee discussed the evidence presented. The committee discussed and agreed the content of the antibiotic choice table.

## **7. Any other business**

No additional items were raised. The meeting closed at 16.00

**Date of next meeting:** Wednesday 19 December 2018, 10.00 – 16.00

**Venue of next meeting:** NICE Office, Manchester